Baskovski Emir, Altin Timucin, Akyurek Omer, Cunetoglu Mahmut Ekrem, Kozluca Volkan, Akbulut Irem Muge, Ozbeyaz Nail Burak, Serifler Nazli Turan, Tutar Eralp
Department of Cardiology Ankara University Ankara Turkey.
Department of Cardiology Ankara Etlik City Hospital Ankara Turkey.
J Arrhythm. 2024 Oct 29;40(6):1425-1431. doi: 10.1002/joa3.13169. eCollection 2024 Dec.
Currently, there are no data regarding outcomes of the catheter ablation for structural ventricular tachycardia (VT) in Türkiye. In this observational study, we aim to investigate cardiac outcomes of patients undergoing catheter VT ablation at a tertiary center in Türkiye.
This was a retrospective observational study performed at a single university center. Patients with a confirmed ischemic or non-ischemic cardiomyopathy, undergoing structural VT ablation were included. Procedural and mid-term outcomes were analyzed.
A total of 124 patients were enrolled in the study. 54(43.5%) patients presented with an electrical storm. During the mean follow-up of 351 ± 232 days 10(8.1%) patients experienced a recurrence. There was only one peri-procedural death and cardiac tamponade occurred in two patients.14(11.3%) patients died during the follow-up, most commonly due to a cardiovascular death. In the multivariate analysis only age >70 was found to be correlated with death during follow-up, with =.008, HR = 4.923.
A good acute success with low complications was observed in patients undergoing VT ablation for structural heart disease in a tertiary center in Türkiye. Mid-term outcomes are comparable with international studies with no difference in VT recurrence in ischemic and non-ischemic patients. Similar to international studies, significant mid-term mortality was observed.
目前,土耳其尚无关于导管消融治疗结构性室性心动过速(VT)疗效的数据。在这项观察性研究中,我们旨在调查在土耳其一家三级中心接受导管VT消融治疗患者的心脏结局。
这是一项在单一大学中心进行的回顾性观察性研究。纳入确诊为缺血性或非缺血性心肌病且接受结构性VT消融治疗的患者。分析手术及中期结局。
共有124例患者纳入研究。54例(43.5%)患者出现电风暴。在平均351±232天的随访期间,10例(8.1%)患者出现复发。围手术期仅1例死亡,2例患者发生心脏压塞。14例(11.3%)患者在随访期间死亡,最常见原因是心血管死亡。多因素分析显示,仅年龄>70岁与随访期间死亡相关,P = 0.008,HR = 4.923。
在土耳其一家三级中心,对患有结构性心脏病的患者进行VT消融治疗,观察到良好的急性成功率且并发症发生率低。中期结局与国际研究相当;缺血性和非缺血性患者的VT复发无差异。与国际研究相似,观察到显著的中期死亡率。